Search En menu ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 100,000,000
    Countries
    Sector(s)
    Italy : € 100,000,000
    Industry : € 100,000,000
    Signature date(s)
    24/07/2014 : € 100,000,000

    Summary sheet

    Release date
    1 October 2013
    Status
    Reference
    Signed | 24/07/2014
    20130211
    Project name
    Promoter - financial intermediary
    BRACCO MEDICAL TECHNOLOGY
    BRACCO SPA
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 100 million
    EUR 215 million
    Location
    Sector(s)
    Description
    Objectives

    Financing of Bracco Group Research and Development activities in the pharma field of contrast media and contrast media injectors.

    It is the objective of this project to further develop contrast media and contrast media injectors.

    Environmental aspects
    Procurement

    The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorized for the same purpose and would therefore not require an EIA under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the promoter’s procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank’s services will verify details during the project due diligence.

    Comments

    The Risk Sharing Finance Facility (RSFF) is an innovative credit risk sharing scheme jointly set up by the European Commission and the European Investment Bank to improve access to debt financing for private companies or public institutions promoting activities with a higher financial risk profile in the fields of research, technological development, demonstration and innovation investments.

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - BRACCO MEDICAL TECHNOLOGY
    Publication Date
    24 Feb 2014
    Document language
    Main Topic
    Lending
    Document Number
    49803342
    Document Focus
    Environmental Information
    Project Number
    20130211
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now
    Environmental and Social Completion Sheet (ESCS) - BRACCO MEDICAL TECHNOLOGY
    Publication Date
    24 Jan 2020
    Document language
    Main Topic
    Lending
    Document Number
    87294596
    Document Focus
    Environmental Information
    Project Number
    20130211
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now

    News & Stories

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications